Korean Journal of Biological Psychiatry (생물정신의학)

The Korean Society of Biological Psychiatry (대한생물정신의학회)
권호 표지

Association of Therapeutic Response and Change of Mismatch Negativity in Schizophrenia Patients

조현병 환자의 치료 반응에 따른 Mismatch Negativity 변화

  • Lee, Soyoen (Department of Psychiatry, Kyung Hee University Hospital) ;
  • Rhie, Eui Hyeok (Department of Biomedical Science, Graduate School, Eulji University) ;
  • Kim, Jong Woo (Department of Psychiatry, Kyung Hee University Hospital) ;
  • Kang, Won Sub (Department of Psychiatry, Kyung Hee University Hospital)
  • 이소연 (경희대학교병원 정신건강의학과) ;
  • 이의혁 (을지대학교 일반대학원 임상병리학과) ;
  • 김종우 (경희대학교병원 정신건강의학과) ;
  • 강원섭 (경희대학교병원 정신건강의학과)
  • Received : 2017.08.03
  • Accepted : 2017.09.22
  • Published : 2017.11.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives Schizophrenia is characterized by disturbances in perception and cognition. Attenuated mismatch negativity (MMN) reflects central auditory dysfunction in schizophrenia. The aim of this study is to compare MMN changes before and after treatment in schizophrenia patients and to assess their association with treatment response. Methods Twenty-three schizophrenia patients underwent an oddball paradigm. MMN was calculated by the difference waveforms of the event-related potentials (ERPs) elicited by subtracting standard from deviant stimulus. The clinical symptoms were measured by the Positive and Negative Syndrome Scale (PANSS), the Psychotic Symptom Rating Scale (PSYRATS). Follow-up evaluation was conducted when the PANSS total score decreased by 30% or more (treatment response group) or before discharge (non-response group). Results The treatment response group showed significantly larger MMN amplitude improvement and latency reduction than the non-response group after treatment (Fz ; mean amplitude p = 0.035, FCz ; p = 0.041). The auditory hallucination group showed shorter latency than that of the group without hallucinations. Additionally, auditory hallucination was associated with prolonged MMN latency and shortened after treatment in the auditory hallucination response group (Fz ; p = 0.048). Conclusions These results suggest that the attenuated MMN amplitude reflects the progression of the disease. The increment of MMN amplitude and shortening of latency after treatment may reflect cognitive functional recovery of central auditory sensory processing.

Keywords

References

  1. Homayoun S, Nadeau-Marcotte F, Luck D, Stip E. Subjective and objective cognitive dysfunction in schizophrenia-is there a link? Front Psychol 2011;2:148.
  2. Pearlson GD. Neurobiology of schizophrenia. Ann Neurol 2000;48:556-566. https://doi.org/10.1002/1531-8249(200010)48:4<556::AID-ANA2>3.0.CO;2-2
  3. Turetsky BI, Calkins ME, Light GA, Olincy A, Radant AD, Swerdlow NR. Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures. Schizophr Bull 2007;33:69-94.
  4. Naatanen R. Selective attention and evoked potentials in humans--a critical review. Biol Psychol 1975;2:237-307. https://doi.org/10.1016/0301-0511(75)90038-1
  5. Shelley AM, Ward PB, Catts SV, Michie PT, Andrews S, McConaghy N. Mismatch negativity: an index of a preattentive processing deficit in schizophrenia. Biol Psychiatry 1991;30:1059-1062. https://doi.org/10.1016/0006-3223(91)90126-7
  6. Naatanen R, Paavilainen P, Rinne T, Alho K. The mismatch negativity (MMN) in basic research of central auditory processing: a review. Clin Neurophysiol 2007;118:2544-2590. https://doi.org/10.1016/j.clinph.2007.04.026
  7. Naatanen R, Jacobsen T, Winkler I. Memory-based or afferent processes in mismatch negativity (MMN): a review of the evidence. Psychophysiology 2005;42:25-32. https://doi.org/10.1111/j.1469-8986.2005.00256.x
  8. Javitt DC, Sweet RA. Auditory dysfunction in schizophrenia: integrating clinical and basic features. Nat Rev Neurosci 2015;16:535-550. https://doi.org/10.1038/nrn4002
  9. Bodatsch M, Brockhaus-Dumke A, Klosterkotter J, Ruhrmann S. Forecasting psychosis by event-related potentials-systematic review and specific meta-analysis. Biol Psychiatry 2015;77:951-958. https://doi.org/10.1016/j.biopsych.2014.09.025
  10. Atkinson RJ, Michie PT, Schall U. Duration mismatch negativity and P3a in first-episode psychosis and individuals at ultra-high risk of psychosis. Biol Psychiatry 2012;71:98-104. https://doi.org/10.1016/j.biopsych.2011.08.023
  11. Nagai T, Tada M, Kirihara K, Yahata N, Hashimoto R, Araki T, et al. Auditory mismatch negativity and P3a in response to duration and frequency changes in the early stages of psychosis. Schizophr Res 2013; 150:547-554. https://doi.org/10.1016/j.schres.2013.08.005
  12. Todd J, Michie PT, Schall U, Karayanidis F, Yabe H, Naatanen R. Deviant matters: duration, frequency, and intensity deviants reveal different patterns of mismatch negativity reduction in early and late schizophrenia. Biol Psychiatry 2008;63:58-64. https://doi.org/10.1016/j.biopsych.2007.02.016
  13. Umbricht D, Krljes S. Mismatch negativity in schizophrenia: a meta-analysis. Schizophr Res 2005;76:1-23. https://doi.org/10.1016/j.schres.2004.12.002
  14. Naatanen R, Kahkonen S. Central auditory dysfunction in schizophrenia as revealed by the mismatch negativity (MMN) and its magnetic equivalent MMNm: a review. Int J Neuropsychopharmacol 2009;12:125-135. https://doi.org/10.1017/S1461145708009322
  15. Kim M, Kim SN, Lee S, Byun MS, Shin KS, Park HY, et al. Impaired mismatch negativity is associated with current functional status rather than genetic vulnerability to schizophrenia. Psychiatry Res 2014;222:100-106. https://doi.org/10.1016/j.pscychresns.2014.02.012
  16. Rosburg T, Kreitschmann-Andermahr I. The effects of ketamine on the mismatch negativity (MMN) in humans-a meta-analysis. Clin Neurophysiol 2016;127:1387-1394. https://doi.org/10.1016/j.clinph.2015.10.062
  17. Kantrowitz JT, Epstein ML, Lee M, Lehrfeld N, Nolan KA, Shope C, et al. Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: correlation with symptoms. Schizophr Res 2017. pii: S0920-9964(17)30116-0.
  18. Nagai T, Kirihara K, Tada M, Koshiyama D, Koike S, Suga M, et al. Reduced mismatch negativity is associated with increased plasma level of glutamate in first-episode psychosis. Sci Rep 2017;7:2258. https://doi.org/10.1038/s41598-017-02267-1
  19. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276. https://doi.org/10.1093/schbul/13.2.261
  20. Haddock G, McCarron J, Tarrier N, Faragher EB. Scales to measure dimensions of hallucinations and delusions: the psychotic symptom rating scales (PSYRATS). Psychol Med 1999;29:879-889. https://doi.org/10.1017/S0033291799008661
  21. CRAN-Package erp.easy [homepage on the Internet]. Vienna: erp. easy: Event-Related Potential (ERP) Data Exploration Made Easy [updated 2017 March 2; cited 2017 Aug 2]. Available from: https://CRAN.R-project.org/package=erp.easy.
  22. Fisher DJ, Labelle A, Knott VJ. Alterations of mismatch negativity (MMN) in schizophrenia patients with auditory hallucinations experiencing acute exacerbation of illness. Schizophr Res 2012;139:237-245. https://doi.org/10.1016/j.schres.2012.06.004
  23. Fisher DJ, Grant B, Smith DM, Borracci G, Labelle A, Knott VJ. Effects of auditory hallucinations on the mismatch negativity (MMN) in schizophrenia as measured by a modified 'optimal' multi-feature paradigm. Int J Psychophysiol 2011;81:245-251. https://doi.org/10.1016/j.ijpsycho.2011.06.018
  24. Kasai K, Shenton ME, Salisbury DF, Hirayasu Y, Lee CU, Ciszewski AA, et al. Progressive decrease of left superior temporal gyrus gray matter volume in patients with first-episode schizophrenia. Am J Psychiatry 2003;160:156-164. https://doi.org/10.1176/appi.ajp.160.1.156
  25. Erickson MA, Ruffle A, Gold JM. A meta-analysis of mismatch negativity in schizophrenia: from clinical risk to disease specificity and progression. Biol Psychiatry 2016;79:980-987. https://doi.org/10.1016/j.biopsych.2015.08.025
  26. Kargel C, Sartory G, Kariofillis D, Wiltfang J, Muller BW. Mismatch negativity latency and cognitive function in schizophrenia. PLoS One 2014;9:e84536. https://doi.org/10.1371/journal.pone.0084536
  27. Grzella I, Muller BW, Oades RD, Bender S, Schall U, Zerbin D, et al. Novelty-elicited mismatch negativity in patients with schizophrenia on admission and discharge. J Psychiatry Neurosci 2001;26:235-246.
  28. Picton TW, Alain C, Otten L, Ritter W, Achim A. Mismatch negativity: different water in the same river. Audiol Neurootol 2000;5:111-139. https://doi.org/10.1159/000013875
  29. Toyomaki A, Kusumi I, Matsuyama T, Kako Y, Ito K, Koyama T. Tone duration mismatch negativity deficits predict impairment of executive function in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:95-99. https://doi.org/10.1016/j.pnpbp.2007.07.020
  30. Umbricht D, Javitt D, Novak G, Bates J, Pollack S, Lieberman J, et al. Effects of risperidone on auditory event-related potentials in schizophrenia. Int J Neuropsychopharmacol 1999;2:299-304. https://doi.org/10.1017/S1461145799001595
  31. Zhou Z, Zhu H, Chen L. Effect of aripiprazole on mismatch negativity (MMN) in schizophrenia. PLoS One 2013;8:e52186. https://doi.org/10.1371/journal.pone.0052186
  32. Oranje B, Aggernaes B, Rasmussen H, Ebdrup BH, Glenthoj BY. Selective attention and mismatch negativity in antipsychotic-naive, firstepisode schizophrenia patients before and after 6 months of antipsychotic monotherapy. Psychol Med 2017;47:2155-2165. https://doi.org/10.1017/S0033291717000599
  33. Korostenskaja M, Dapsys K, Siurkute A, Maciulis V, Ruksenas O, Kahkonen S. Effects of olanzapine on auditory P300 and mismatch negativity (MMN) in schizophrenia spectrum disorders. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:543-548. https://doi.org/10.1016/j.pnpbp.2005.01.019
  34. Umbricht D, Javitt D, Novak G, Bates J, Pollack S, Lieberman J, et al. Effects of clozapine on auditory event-related potentials in schizophrenia. Biol Psychiatry 1998;44:716-725. https://doi.org/10.1016/S0006-3223(97)00524-6
  35. During S, Glenthoj BY, Oranje B. Effects of blocking D2/D3 receptors on mismatch negativity and P3a amplitude of initially antipsychotic naive, first episode schizophrenia patients. Int J Neuropsychopharmacol 2016;19:pyv109.
  36. Laruelle M, Frankle WG, Narendran R, Kegeles LS, Abi-Dargham A. Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation. Clin Ther 2005;27 Suppl A:S16-S24. https://doi.org/10.1016/j.clinthera.2005.07.017
  37. Ceglia I, Carli M, Baviera M, Renoldi G, Calcagno E, Invernizzi RW. The 5-HT receptor antagonist M100,907 prevents extracellular glutamate rising in response to NMDA receptor blockade in the mPFC. J Neurochem 2004;91:189-199. https://doi.org/10.1111/j.1471-4159.2004.02704.x